Certara Divests Subsidiary, Shifts Strategic Focus. The pharmaceutical software company sold its regulatory and medical writing business for up to $135 million, positioning itself with a net cash balance sheet and simplified operations centered on AI-integrated drug modeling. Post-divestiture, Certara gains financial flexibility but faces near-flat organic growth prospects and ongoing uncertainty around artificial intelligence disruption in its core markets. Valuation multiples have compressed to approximately 2.6x sales and 8x EBITDA, with shares trading near historic lows despite the improved balance sheet and unleveraged capital structure. The stock trades at roughly 20x forward earnings, presenting a cautious opportunity for investors monitoring whether the company can reignite growth and successfully integrate AI technologies into its business model moving forward.
Post from MarketNews_en
Log in to interact with content.